Table 3.

Demographic and clinical characteristics of participating psoriasis patients

	Sampled psoriasis patients (n = 196)a
Severity of psoriasis symptoms at its worst
Moderate	89 (45.4%)
Severe	107 (54.6%)
Years since psoriasis diagnosis
< 1 year	10 (5.1%)
1–5 years	81 (41.3%)
6–10 years	44 (22.4%)
11–20 years	30 (15.3%)
21+ years	31 (15.8%)
Current treatment for psoriasis
Adalimumab	34 (17.3%)
Etanercept	32 (16.3%)
Infliximab	18 (9.2%)
Ustekinumab	16 (8.2%)
Apremilast	15 (7.7%)
Secukinumab	12 (6.1%)
Doctor most frequently seen for psoriasis
Dermatologist	116 (59.2%)
Rheumatologist	32 (16.3%)
Other (i.e., PCP)	48 (24.5%)
Male	79 (40.3%)
Age
18–29 years old	27 (13.8%)
30–39 years old	82 (41.8%)
40–49 years old	39 (19.9%)
50–69 years old	43 (21.9%)
70+ years old	5 (2.6%)
Ethnicity
Non-Hispanic White	155 (79.1%)
Hispanic or Latino	22 (11.2%)
Non-Hispanic Black or African American	12 (6.1%)
Other (e.g., Asian/Pacific Islander, Native American)	7 (3.6%)

Values are count (%)

PCP primary care physician